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ORIGINAL ARTICLE
Genome-wide analysis of rare copy number variations reveals
PARK2 as a candidate gene for attention-deficit/hyperactivity
disorder
I Jarick1, A-L Volckmar2, C Pu¨tter3, S Pechlivanis3, TT Nguyen1, MR Dauvermann2,4, S Beck2, O¨ Albayrak2, S Scherag2,
S Gilsbach5, S Cichon6,7,8, P Hoffmann7,8, F Degenhardt7,8, MM No¨then7,8,9, S Schreiber10, H-E Wichmann11, K-H Jo¨ckel3, J Heinrich11,
CMT Tiesler11,12, SV Faraone13, S Walitza14, J Sinzig15,16, C Freitag17, J Meyer18, B Herpertz-Dahlmann5, G Lehmkuhl15, TJ Renner19,
A Warnke19, M Romanos19,20, K-P Lesch21,22, A Reif23, BG Schimmelmann2,4, J Hebebrand2, A Scherag3,24 and A Hinney2,24
Attention-deficit/hyperactivity disorder (ADHD) is a common, highly heritable neurodevelopmental disorder. Genetic loci
have not yet been identified by genome-wide association studies. Rare copy number variations (CNVs), such as chromosomal
deletions or duplications, have been implicated in ADHD and other neurodevelopmental disorders. To identify rare
(frequency p1%) CNVs that increase the risk of ADHD, we performed a whole-genome CNV analysis based on 489 young ADHD
patients and 1285 adult population-based controls and identified one significantly associated CNV region. In tests for a
global burden of large (4500 kb) rare CNVs, we observed a nonsignificant (P¼ 0.271) 1.126-fold enriched rate of subjects carrying
at least one such CNV in the group of ADHD cases. Locus-specific tests of association were used to assess if there were more rare
CNVs in cases compared with controls. Detected CNVs, which were significantly enriched in the ADHD group, were validated by
quantitative (q)PCR. Findings were replicated in an independent sample of 386 young patients with ADHD and 781 young
population-based healthy controls. We identified rare CNVs within the parkinson protein 2 gene (PARK2) with a significantly
higher prevalence in ADHD patients than in controls (P¼ 2.8 10 4 after empirical correction for genome-wide testing). In total,
the PARK2 locus (chr 6: 162 659 756–162 767 019) harboured three deletions and nine duplications in the ADHD patients and
two deletions and two duplications in the controls. By qPCR analysis, we validated 11 of the 12 CNVs in ADHD patients
(P¼ 1.2 10 3 after empirical correction for genome-wide testing). In the replication sample, CNVs at the PARK2 locus were
found in four additional ADHD patients and one additional control (P¼ 4.3 10 2). Our results suggest that copy number variants
at the PARK2 locus contribute to the genetic susceptibility of ADHD. Mutations and CNVs in PARK2 are known to be associated with
Parkinson disease.
Molecular Psychiatry (2014) 19, 115–121; doi:10.1038/mp.2012.161; published online 20 November 2012
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INTRODUCTION
Attention-deficit/hyperactivity disorder (ADHD) represents one of
the most common psychiatric disorders in children and adoles-
cents with a worldwide prevalence rate of 5.2%.1 According to the
Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV),2 ADHD is characterized by pervasive and
impairing symptoms of inattention, hyperactivity and increased
impulsivity. Family, twin and adoption studies indicate that ADHD
is a highly heritable disorder; heritability estimates are consistently
around 0.8.3–7 However, neither genome-wide association studies
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(GWAS) nor large scale meta-analyses of GWAS has so far
unequivocally identified specific genes conferring major risk (see
Hinney et al.8).
Copy number variations (CNVs) are, by definition, chromosomal
deletions or duplications of at least 1 kb up to several Mb that are
variable in size among carriers. At a genome-wide level, thousands
of CNVs have already been identified. Several CNVs were shown to
contribute to neurodevelopmental disorders such as schizophre-
nia,9 Parkinson disease (PD)10 or autism.11 Five genome-wide
analyses of CNVs have been published in ADHD.12–16 Rare CNVs
identified in ADHD patients were found to be preferentially
located in neurodevelopmental genes,12 that is, in genes reported
as candidates in other neuropsychiatric disorders, such as autism,
schizophrenia and Tourette syndrome, and in neurodevelop-
mental pathways. Large (4500 kb), rare (p1% frequency) CNVs
were found with an increased rate in British children with ADHD
compared with controls from the British Birth Cohort. Locus-
specific analyses revealed that this finding was largely based on
several large CNVs in the chromosome 16p13.11 region; results for
this region could be replicated in an Icelandic ADHD case–control
sample.13 A second candidate region presumably harbouring
CNVs associated with ADHD comprises the neuropeptide Y gene
(NPY). The suggestive finding was based on a sample of 99
German children and adolescents with severe ADHD who were
characterized by array comparative genomic hybridization.14
Recently, the detection of rare CNVs, which were present in
Canadian ADHD cases but absent in a population-based control
sample, identified new candidate ADHD susceptibility genes.15 A
comparison of 896 ADHD cases with 2455 controls of European
ancestry reported a significant excess of rare CNVs 4100 kb
among patients with ADHD.16 The strongest evidence for a single
CNV locus was for duplications spanning the CHRNA7 gene
(15q13.3). This finding was replicated in additional 2242 ADHD
cases and 8552 controls. In addition, an overlap between
nominally associated CNV and single nucleotide polymorphism
(SNP) data was detected for 13 enriched biological
pathways (including cholesterol-related and CNS developmental
pathways), and for 1 specific candidate at the gene level:
CHRNA717. Elia et al.18 reported CNV analyses for 2493 ADHD
cases and 9222 controls of European ancestry. They found an
enrichment of CNVs in metabotropic glutamate receptor genes in
patients with ADHD.
We followed-up the mentioned previous findings by investigat-
ing the hypothesis of ‘common disease—many rare variants’19 in
our study. In more detail, we investigated the role of rare CNVs in
ADHD by performing a genome-wide CNV association study in
489 patients with ADHD and 1285 population-based control
individuals based on Illumina SNP arrays (Illumina Ltd, Little
Chesterford, UK; ADHD patients: Human660W-Quadv1; controls:
HumanHap550v3 BeadArrays). We searched for regions where
ADHD patients had an increased number of CNVs (deletions and
insertions) compared with controls. Replication of our findings was
conducted in an independent sample of 386 patients with ADHD
and 781 healthy controls on the basis of genome-wide Affymetrix
SNP array data (Affymetrix Genome-Wide Human SNP Array 5.0,
Affymetrix Ltd, High Wycombe, UK).
MATERIALS AND METHODS
Participants
GWAS sample. In total, 504 patients recruited for the GWAS step (see
Hinney et al.8) were assessed for the diagnosis ADHD according to
DSM-IV.2 The corresponding subtypes and basic characteristics of those
489 ADHD patients whose molecular data met our pre- and post-calling
quality control (QC) criteria (see Supplementary Text) are given in Table 1.
The GWAS cases are all German minors (age range: 6–18 years, mean age:
11.0±2.7 years) with ADHD, recruited and phenotypically characterized in
six psychiatric outpatient units for children and adolescents (Aachen,
Cologne, Essen, Marburg, Regensburg and Wu¨rzburg). The ascertainment
strategy and inclusion criteria have been described previously.20–22
In addition, controls not screened for ADHD were drawn from three
German population-based epidemiological studies in adults (for details see
Cichon et al.23) for the GWAS step: (a) the Heinz Nixdorf RECALL
(Risk Factors, Evaluation of Coronary Calcification, and Lifestyle) study24
(HNR, n¼ 383), (b) PopGen25 (n¼ 490) and (c) KORA26 (n¼ 488). The
recruitment areas were Essen, Bochum and Mu¨lheim (Ruhr area) for (a),
Schleswig-Holstein (Northern Germany) for (b) and Augsburg (Southern
Germany) for (c), respectively. Molecular data from 1285 of the 1361
controls (see Table 1) met our pre- and post-calling QC criteria. Compared
with the ADHD cases, the population-based controls were less frequently
male (cases: 81.0% male; controls: 50.7% male) and older (age range cases:
6–18 years; age range controls: 25–75 years).
Replication sample. The case group of the replication sample consisted of
461 young (age range: 6–19 years, mean age: 10.4±2.4 years) patients of
German ancestry with ADHD, who were recruited and phenotypically
characterized in two outpatient clinics at the Departments of Child and
Adolescent Psychiatry, Psychosomatics and Psychotherapy of the Uni-
versities of Homburg and Wu¨rzburg, Germany. Patients were included if
they were diagnosed with ADHD according to DSM-IV2, subtypes and basic
characteristics of the 386 analysed (after pre- and post-calling QC) ADHD
cases are given in Table 1. The ascertainment strategy and inclusion criteria
have been described previously.22,27 Core descriptive statistics of the
ADHD cases of the replication sample were comparable to those of the
ADHD GWAS sample (83.7% male; age range: 6–19 years).
For the replication sample, 1063 controls were chosen from two
ongoing German population-based prospective birth cohorts: the influ-
ence of life-style factors on the Immune System and Allergies Plus
environment and genetics (LISAplus)28 study and the German Infant study
on the influence of Nutrition Intervention Plus environment and genetics
(GINIplus).29 Briefly, the two birth cohorts consist of healthy full-term
newborns, who were recruited between September 1955 and January
1999 in Munich, Wesel, Leipzig and Bad Honnef and followed-up to age 10.
A detailed description of screening and recruitment has been provided
elsewhere.28,29 Any probands without questionnaire information (n¼ 111)
or who were categorized as above the normal range at the age of 10 on
the Strengths and Difficulties Questionnaire on the scales for hyperactivity/
inattention or with the Strengths and Difficulties Questionnaire total
difficulties score (n¼ 118) were excluded from the analysis (n¼ 229). A
summary of the 781 analysed (after pre- and post-calling QC) replication
controls is provided in Table 1.
Ethnicity in both the GWAS and the replication sample was assigned to
patients and controls according to self-reported ancestry (all German).
Written informed consent was given by all individuals or by their parents in
case of minors. The study protocols were approved by the respective
Institutional Review Board or Ethics Committees and they were conducted
in accordance with The Declaration of Helsinki.
Statistical analysis
Details on genotyping, the procedures for CNV detection and QC for CNV
calls are given in the Supplementary Text. All association analyses were
performed on the QC filtered, rare CNV calls were investigated using the
PLINK software (version 1.07).30 As primary analyses, we tested the
hypothesis that particular rare CNVs might be found at an increased
frequency in ADHD cases compared with controls. Locus-specific tests of
association were performed (one-sided w2 tests) and significance was
assessed via permutation (empirical P-values based on 100 000
permutations) at a pointwise as well as at a genome-wide level. In more
detail, we calculated the frequency of rare CNVs in ADHD patients, and we
compared it to the frequency in the controls. The frequency was calculated
at each unique start and stop site for rare CNVs that met all of the defined
QC measures (defined in the Supplementary Text). Each site (5047 sites in
total, located in 1083 non-overlapping genomic CNV containing regions)
was assessed for a difference in CNV frequency between groups with the
use of a permutation-based Fisher’s exact test in PLINK. We refer to a locus
in the sense of a susceptibility locus as a genomic region that is exclusively
made up of adjacently tested sites for which significantly more rare CNVs
were observed in ADHD cases than in controls. These analyses were
undertaken for all rare CNVs as well as stratified according to CNV type,
that is, deletion or duplication. In the GWAS sample, empirical, genome-
wide corrected P-values were generated by permuting affection status and
simultaneously preserving the correlation structure of CNVs (100 000
CNV GWAS reveals PARK2 as a candidate for ADHD
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permutations) to simulate the null hypothesis of no association. In other
words, we used the permutation resampling method to correct for the
multiple testing problem, which occurs when testing any identified locus
of rare CNVs.
By application of PLINK’s case–control ‘cnv-enrichment-test’ function, we
additionally tested whether CNVs in the PARK2 gene are enriched in ADHD
GWAS cases compared with GWAS controls. In contrast to Fisher’s exact
test, the ‘cnv-enrichment-test’ is robust to case–control differences in CNV
size or CNV rate.31 Enrichment in cases is reported as one-sided empirical
P-value using 100 000 permutations.
Analysis of the replication sample was performed to confirm the finding
of the GWAS sample at the PARK2 locus (Results section) and we focussed
the testing on this single rare CNV locus for an association to ADHD.
Consequently, pointwise empirical P-values (100 000 permutations) for the
replication sample were not corrected for multiple testing. The statistical
analyses in the GWAS sample were repeated for quantitative (q)PCR-
validated CNVs at the PARK2 locus as part of the sensitivity analysis. We
applied a significance level a of 0.05 (globally for the genome-wide testing
and locally for the replication sample).
As secondary sensitivity analyses (see Supplementary Text), we also
assessed the genome-wide frequency of CNVs in ADHD cases compared
with controls according to the average number of CNVs per sample. We
expected more CNVs in the ADHD cases based on the literature.32 Thus,
one-sided tests were applied to all rare CNVs, as well as to rare deletions
and duplications only; and genome-wide multiple testing was dealt with
using 100 000 permutations. Finally, we likewise tested whether CNVs in
the ADHD cases were larger in size than those in the control group based
on the average size of CNVs per individual.
CNV validation and replication analysis at the PARK2 locus
We performed real-time qPCR experiments to validate the CNVs by a
Duplex TaqMan CNV assay (Applied Biosystems, Darmstadt, Germany,
assay Hs03615859_cn at chr6: 162 696 987±50 bp, NCBI36/hg18) as
described previously.33 Individual copy number status was determined
for each ADHD patient of the GWAS sample. Briefly, every PCR was
performed as a triplicate for each individual of the GWAS ADHD cases and
the results from the qPCR were analysed using the software CopyCaller 1.0
(Applied Biosystems). In cases, 11 of the 12 CNVs identified with PennCNV
covering the PARK2 locus (Results section) were technically validated by
qPCR. qPCR experiments did not reveal any further CNV carrier, which was
undetected in previous SNP array-based CNV detection analyses. Thus,
CNVs at the PARK2 locus of GWAS ADHD patients could be validated with
both, a low false-positive and a low false-negative rate. For a subset of
controls (HNR controls), CNV calls, which were estimated to cover the
PARK2 gene, were validated by qPCR. Apart from one potential CNV carrier,
who was incorporated into statistical analysis at the PARK2 locus, we
additionally considered the five HNR controls for which CNVs were
estimated to flank the PARK2 locus (n¼ 3) or for which CNVs were called
but excluded due to their small size (spannedo15 probes) in the course of
our CNV QC procedure (n¼ 2). Moreover, we additionally included six
randomly chosen control subjects of the HNR control sample. CNV analyses
were performed blinded to the likely CNV status of the controls. For the
PARK2 locus, all analysed CNV states could be validated. For the KORA and
PopGen controls, no DNA was available for qPCR validation. However,
given the high technical validation rate in the available DNA samples,
validity of CNV calls was presumed to be comparably high for KORA and
PopGen controls. Although false-negative and false-positive rates are
unknown for the GWAS controls group, there is no obvious reason to
expect that these rates would significantly differ between cases and
controls. Notably, the low frequency of PARK2 CNVs in control subjects was
consistently reported in the ‘Database of Genomic Variants’ (http://
projects.tcag.ca/variation) and in two previous publications, where CNVs
at the PARK2 gene were absent in 2026 healthy, population-based
controls12 and in 1409 healthy children,11 respectively. In a conservative
manner, we excluded the non-validated CNV from the ADHD group,
whereas all four CNVs in the control group were included in all analyses.
We tested the CNV association with ADHD in the PARK2 gene in an
independent replication sample. Details on genotyping, CNV calling and
QC are described in the Supplementary Text.
RESULTS
The GWAS sample included 489 ADHD cases and 1285 controls
(Table 1) with high-quality SNP array data for full CNV analysis.
Comparison of the CNV sets identified in the ADHD patients and in
the controls showed no increased overall frequency of CNVs in
ADHD cases (Supplementary Text). After exclusion of common
(frequency41%) CNVs, 2432 rare CNVs (592 in ADHD cases; 1840
in controls) with an increased length in ADHD cases (average CNV
size: 226.3 kb (range: 9.3–2830.8 kb) in ADHD cases; 186.4 kb
(range: 5.6–4479.6 kb) in controls) were included in the association
analysis. Although there was a difference in the sex distribution
between ADHD patients (81.0% males) and control subjects (50.7%
males), there was no evidence for significant difference in the rate
at which rare CNVs were called in males compared with females in
either cases or comparison subjects (data not presented). All rare
CNVs 4500 kb are listed in Supplementary Table S1.
With regard to previous observations,13,16,17 we first looked at
our data with respect to a potential overall enrichment of rare
CNVs in ADHD cases compared with controls (Supplementary
Table S7) and in terms of an enrichment for loci implicated in
neurodevelopmental disorders, such as autism or schizophrenia
(data not shown). There was no evidence for an increased burden
of rare CNVs in ADHD patients (P¼ 0.997). We additionally
performed comparative analyses on rare CNVs stratified by their
size. Interestingly, with increasing size thresholds, we observed a
Table 1. Descriptive data for ADHD cases and controls following QC of the GWAS and the replication step
GWAS ADHD cases GWAS controlsa Replication ADHD cases Replication controls
Total, n 489b 1285c 386d 781e
Sex
Male, n (%) 396 (81.0%) 651 (50.7%) 323 (83.7%) 402 (51.5%)
Female, n (%) 93 (19.0%) 634 (49.3%) 63 (16.3%) 379 (48.5%)
Age, mean (s.d.; years) 11.0 (2.7) — 10.5 (2.5) 10.0 (0.2)
ADHD subtypef
Combined type, n (%) 360 (73.6%) — 316 (81.9%) 0 (0%)g
Predominantly inattentive type, n (%) 105 (21.5%) — 55 (14.2%) 0 (0%)g
Predominantly hyperactive-impulsive type, n (%) 24 (4.9%) — 15 (3.9%) 0 (0%)g
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; GWAS, genome-
wide association study; QC, quality control.
aThe GWAS controls were not screened. Their age ranges from 25 to 75 years. ADHD subtypes are unknown.
bA total of 504 ADHD patients were recruited for the GWAS step, after QC 489 ADHD patients were left for full analysis.
cA total of 1361 controls were recruited for the GWAS step, after QC 1285 probands were left for full analysis.
dA total of 461 ADHD patients were recruited for the replication step, after QC 386 ADHD patients were left for full analysis.
eA total of 1063 controls were recruited for the replication step, after QC 781 probands were left for full analysis.
fCurrent DSM-IV2 diagnosis.
gForty-four of the 781 controls for the full analysis of the replication step were categorized as borderline on the SDQ hyperactivity/inattention scale.
CNV GWAS reveals PARK2 as a candidate for ADHD
I Jarick et al
117
& 2014 Macmillan Publishers Limited Molecular Psychiatry (2014), 115 – 121
stronger trend of association between large, rare CNVs and ADHD,
which is in accordance with the reports of previous studies.13,16
Despite the fact that none of the comparisons resulted in a
nominally significance (that is, Po0.05): there was a 1.126-fold
enriched rate (P¼ 0.271) and a 1.133-fold higher proportion
(P¼ 0.253) of subjects carrying at least one rare CNV 4500 kb in
the ADHD cohort. The rate of rare CNVs 4500 kb observed in
ADHD cases was 10.4%, which is similar to the rates of 12.2 and
12.5% reported in previous studies.13,16 Limiting our analysis to
rare CNVs 42Mb, we observed a 3.065-fold enrichment
(P¼ 0.074) in ADHD cases relative to control subjects. However,
due to the potential bias in individual CNV rate and average
size, which differentiates cases and controls in our GWAS sample
(see Supplementary Text), we did not follow-up these data.
Differences between distributions in cases and controls may
rather result from different technical genotyping procedures, than
indicating association effects.
Locus-specific association tests for an overrepresentation of
CNVs, including both deletions and duplications, in ADHD cases in
comparison with controls revealed only one genome-wide
significant genomic region within the PARK2 gene with a P-value
of 2.8 10 4 empirically corrected for genome-wide testing
(Figure 1, Supplementary Table S8). This locus for which we
observed more rare CNVs in ADHD cases than in controls is
located at chr6: 162 659 756—162 767 019 (NCBI36/hg18). We
refer to this region as the PARK2 locus. In total, this locus is
covered by 12 CNVs among the ADHD patients (2.45%, three
deletions (0.61%) and nine duplications (1.84%)) and four CNVs
among the controls (0.31%, two deletions (0.16%) and two
duplications (0.16%)), all these CNVs extend into the coding region
(either exon 2 or exon 3) of PARK2. Locus-specific association tests,
stratified according to CNV type (deletion or duplication), did not
reveal further genomic regions with genome-wide significant
results. The PARK2 locus alone showed a genome-wide significant
enrichment of duplications in ADHD cases compared with controls
(P¼ 1.9 10 3 after empirical correction for genome-wide
testing, Figure 1). In contrast, we did not observe a genome-wide
significant excess of deletions for any of the tested regions
harbouring rare CNVs.
Enrichment of CNVs at the PARK2 gene for GWAS ADHD cases
compared with GWAS controls was also supported by the robust
‘cnv-enrichment-test’31 (one-sided empirical P¼ 8.8 10 4).
Copy number status at the PARK2 locus of all ADHD patients in
the GWAS sample was reevaluated by qPCR analyses (Figure 1).
Apart from one duplication, each CNV status was technically
validated. Even after reanalysis of all rare CNVs with exclusion of
the non-validated duplication, the finding for the PARK2 locus
remained genome-wide significant (empirically corrected P¼ 1.2
 10 3, Supplementary Figure S7). We observed no differences in
ADHD subtypes or basic characteristics like age, sex and
intelligence quotient (IQ) values between carriers of CNVs at the
PARK2 locus and the 489 ADHD patients of the GWAS sample
(Supplementary Table S2).
Next, we assessed an independent sample of 386 ADHD
patients and 781 healthy controls to replicate our finding of an
excess of CNVs in ADHD patients at the PARK2 locus. We replicated
the excess (P¼ 4.3 10 2, Figure 1) of CNVs in the ADHD
replication sample (n¼ 4 (1.04%), two duplications (0.52%) and
Figure 1. Results for the PARK2 locus in the GWAS and in the
replication sample. Each panel consists of four parts (called CNVs,
PARK2 gene, probes analysed and association tests): CNVs: red (pink)
bars represent duplications in an ADHD case (control), blue
(lightblue) bars indicate a deletion of an ADHD case (control).
PARK2 gene: the marks indicate the coding regions (NCBI36/hg18).
Association tests: permutation-based one-sided  log10-trans-
formed P-values for association tests; the black (pink; lightblue) line
represents association tests for an increased frequency of segmental
CNV data independent of type (deletions; duplications) in cases
compared with controls. The significance level P¼ 0.05 is high-
lighted as a dashed red line. The chromosomal region offering
genome-wide significantly more CNVs in ADHD patients than in
controls is highlighted by grey vertical shading. (a) Results for the
GWAS sample. The presented P-values are genome-wide empirically
corrected. The chromosomal region covered by the qPCR assay used
for validation of PennCNV’s CNV calls is shown as a darkgrey vertical
dashed line within this region of genome-wide significance. The
duplication that could not be validated by qPCR analysis is marked
by ‘x’. Results of association tests after exclusion of the non-validated
case duplication are shown in Supplementary Figure S7. (b) Results
for the replication sample. The presented P-values are pointwise
corrected.
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two deletions (0.52%)) compared with replication controls (one dupli-
cation (0.13%)). Similar to the initial finding, four of the five CNVs in
the PARK2 locus extend into the coding exon 2 of the gene. Owing
to the small number of CNVs we did not stratify by CNV status.
Finally, in addition to our GWAS discovery analysis, we assessed
ADHD CNV candidate loci from previous reports12–18 in our GWAS
sample using a hypothesis driven approach. First, we did not
identify any putative CNV carrier at the NPY locus.14 Second, we
found a total of eight CNVs (four in cases (one duplication and
three deletions), four in controls (one duplication and three
deletions); Supplementary Figure S8) at the chr 16p13.11 locus.13
Six of the eight CNVs were4500 kb (four in cases (one duplication
and three deletions), two in controls (both deletions); uncorrected
P¼ 0.053 (0.13 for deletions, 0.28 for duplications)). Thus, our data
partly support the relevance of CNVs of the chromosome
16p13.11 locus for ADHD. Third, we determined the number of
CNVs identified in our GWAS sample that overlapped with any of
the 28 reported CNVs as well as with the corresponding 22
candidate genes reported by Elia et al.12 (Supplementary Tables S3
and 4). In addition to PARK2, we reidentified two further genes,
CHL1 and PTPRD, with a higher frequency of CNVs in ADHD
patients compared with controls. We identified two CNVs (one
deletion, one duplication) in ADHD patients (patients frequency
(Fpatients)¼ 0.41%) and one deletion in the controls (controls
frequency (Fcontrols)¼ 0.08%) that overlapped CHL1. The set of
CNVs involving PTRD included three deletions in ADHD patients
(Fpatients¼ 0.61%) and five CNVs (four deletions and one duplica-
tion) in controls (Fcontrols¼ 0.39%). Fourth, we did not identify any
CNVs at GRM5, GRM8, GRM7 or GRM1.18 Finally, we compared the
frequency of CNVs identified in our GWAS ADHD cases and
controls that overlapped with any of 22 rare CNV loci exclusively
found in Canadian ADHD patients and not in Canadian or German
population-based controls15 (Supplementary Tables S5 and 6). For
two loci, at chr 6p24.2 (covering GCNT2) and at chr 16p11.2, we
reidentified one CNV exclusively in ADHD cases (Fpatients¼ 0.20%),
respectively. In addition, we observed two further loci with higher
frequencies of CNVs in ADHD cases than in controls. We found
four duplications (Fpatients¼ 0.82%) in ADHD patients and seven
duplications (Fcontrols¼ 0.54%) in the controls at the chr 7q36.3
locus (covering PTPRN2); as well as five duplications in ADHD cases
(Fpatients¼ 1.02%) and eight CNVs (one deletion, seven duplica-
tions) in the controls (Fcontrols¼ 0.62%, deletions: Fcontrols¼ 0.08%,
duplications: Fcontrols¼ 0.54%) at the chr 15q13 locus.16,17
DISCUSSION
Within two moderately sized ADHD case–control samples, we
showed that children with ADHD have a significantly increased
frequency of CNVs, including both deletions and duplications, at
the PARK2 locus compared with controls. The initial impression
based on the observations in the GWAS sample, that this excess of
CNVs at the PARK2 locus is mainly driven by duplications, could
not be substantiated in the replication sample. In conclusion, our
data indicate that the PARK2 locus influences susceptibility to
ADHD when it comprises either deletions or duplications. Similarly,
deletions and duplications on chromosome 16p11.2 were
previously observed to be collectively associated with autism.34
Moreover, CNVs at chromosome 1q21.1 were shown to be
associated with congenital heart defects, developmental delay,
schizophrenia and related psychoses,35 whereas more recently
microcephaly and macrocephaly were consistently observed in
patients with 1q21.1 deletions and duplications, respectively,
along with a spectrum of developmental delay, neuropsychiatric
abnormalities, dysmorphic features and congenital anomalies.35
Regarding CNVs at the PARK2 locus, their role in the genetics of
ADHD needs to be further investigated in more detail.
Interestingly, the PARK2 gene, which was previously associated
with schizophrenia,36 was one of the neurodevelopmental genes
that were identified to harbour CNVs in ADHD cases but not in
healthy controls in the first published genome-wide investigation
of CNVs in ADHD.12 However, in the study by Elia et al. CNVs in the
PARK2 gene did not achieve genome-wide significance—two CNVs
were found in 335 ADHD cases and none in 2026 healthy controls.
The precise function of the PARK2 gene, which encodes parkin, is
unknown; however, the encoded protein is a component of a
multiprotein E3 ubiquitin ligase complex that mediates the
targeting of substrate proteins for proteasomal degradation. Parkin
was suggested to increase dopamine uptake by enhancing the
ubiquitination and degradation of misfolded dopamine transporter,
so as to prevent it from interfering with the oligomerization and
cell surface expression of native dopamine transporter.37 With this
function, parkin would enhance the precision of dopaminergic
transmission, increase the efficiency of dopamine utilization and
reduce dopamine toxicity on neighbouring cells.37 Mutations in the
PARK2 gene have been reported as a cause of PD38 and autosomal
recessive juvenile PD.38 Alternative splicing of this gene produces
multiple transcript variants encoding distinct isoforms. Additional
splice variants of this gene have been described but currently lack
transcript support.39 CNVs within or surrounding genes involved in
the ubiquitin pathway, including among others PARK2, were
observed to be significantly enriched in cases affected by autism
spectrum disorders compared with a healthy control cohort.11
More recently, PARK2 CNVs (including deletions and duplications)
were also shown to be associated with PD susceptibility.10 Fitting to
these results is an observation, we have described earlier in a
clinical retrospective study including patients with early and late
onset PD that found association of PD with symptoms of ADHD in
childhood.40 In addition, the PARK2 gene, including rare inherited
copy number changes at this locus, was also implicated in a study
pertaining to schizophrenia.36
CNVs at the PARK2 locus were shown to be significantly more
common in children with ADHD but were not restricted to this
group. Furthermore, among the ADHD patients of the GWAS
sample, carriers of CNVs covering the PARK2 locus showed no
differences from non-carriers by ADHD subtype, age, sex or IQ
values. This observation is in concordance with recent results that
showed a general lack of differences in clinical or cognitive
characteristics between children with ADHD, with and without
large rare CNVs.41 The only reported significant difference was a
higher rate of intellectual disability (IQ o70) among CNV carriers
compared with non-carriers, whereas most CNV carriers did not
have an intellectual disability. As an IQ 470 was an inclusion
criteria for our study, we could not analyse CNV burden according
to IQ value and thus unfortunately could not compare our results
with the mentioned study.41
Apart from the PARK2 locus, our observations support findings
of previous studies.12,13,15 In parts, we substantiated the relevance
of CNVs at the chromosome 16p13.11 locus for ADHD. The
consensus region of large CNVs at chromosome 16p13.11 spans
seven genes: MPV17L, C16orf45, KIAA0430, NDE1, MYH11, C16orf63
and ABCC1. Of particular interest is the nuclear distribution gene E
homologue 1 (NDE1), which regulates neuronal activity and
interacts with the disrupted in schizophrenia 1 gene, a risk factor
for schizophrenia and related illnesses.42 CNVs spanning this gene
region have also been associated with intellectual disability,43
autism43 and schizophrenia.44 We also found an excess of CNVs,
and particular of duplications, in the 15q13.3 region spanning
CHRNA7, which was the strongest finding from the Williams et al.16
ADHD CNV study. Moreover, our data support evidence for their
potential role in ADHD for CNVs covering four genes additional to
PARK2: CHL1, PTPRD, GCNT2 and PTPRN2. Previously, CNVs
spanning these genes were exclusively found in ADHD
patients.12,15 In our study, CNVs covering the genes PARK2,
CHL1, PTPRD and PTPRN2 were observed at a higher frequency in
ADHD patients compared with controls. A deletion covering
GCNT2 was exclusively found in one ADHD patient. Missense
CNV GWAS reveals PARK2 as a candidate for ADHD
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mutations in the CHL1 gene were identified to be associated with
schizophrenia.45 Then, SNPs in PTPRD were identified as risk
factors for the restless legs syndrome46 and disruptions of the
GCNT2 gene have previously been reported in autism spectrum
disorders.47 Finally, with regard to previous reports of ADHD being
a frequent phenotypic component in patients with deletions or
duplications at 15q13 and 16p11.2,48,49 our results underline the
role of rare CNVs at these two loci for ADHD. However, the
investigation of loci previously implicated in ADHD in our sample
is limited by statistical power. The modest P-values we obtained at
each locus are almost certainly the result of this limited power to
detect rare variants.
With regard to reported results of previous studies,13,16 we
additionally tested for a global burden of rare CNVs in ADHD cases
relative to control subjects. Although not reaching significance, we
consistently observed a trend for an overall enrichment of large
(4 500 kb), rare CNVs harboured by ADHD cases compared with
controls. However, as CNVs were not validated at the genome-
wide level, these results need to be interpreted with caution.
As our study is based on custom genotyping chips, it remains to
be determined whether a sequencing approach or the use of
higher-resolution platforms would detect a broader range of rare
CNVs associated with ADHD. In addition, much larger sample sizes
may yield sufficient power to detect common genetic variants
with modest or marginal effects. With respect to the use of
different SNP arrays, we limited our analysis to the intersecting set
of SNPs between chip platforms and applied conservative quality-
control criteria. Nevertheless, our observation that rare CNVs in
ADHD patients were on average larger but less frequent than
those in controls (see Supplementary Text) may in part be
explained by the inability of a precise determination of CNV
breakpoints on the basis of SNP chip data. To support our main
finding, however, the association of PARK2 CNVs with ADHD was
validated by qPCR and replicated in an independent sample.
In summary, our results support the role of structural variants at
the PARK2 locus for ADHD genetics. Moreover, our data support
the further investigation of CNVs involving neurodevelopmental
genes, such as CHL1, PTPRD, GCNT2, PTPRN2 and NDE1, as well as
deletions and duplications at the 15q13 and 16p11.2 regions for
ADHD genetics.
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